Please enable Javascript
Patrick Daly
Patrick Daly is an Assistant Editor at AMC Media Group.
Articles by Patrick Daly
Polycythemia Vera-Associated Iron Deficiency Rapidly Managed with Rusfertide
Patrick Daly
Polycythemia Vera
|
December 8, 2023
Rusfertide quickly induced hematocrit control and maintained improved levels over time in patients with polycythemia vera.
Read More
Long-term Data Supports CAR T-cells in Earlier Lines of Therapy for MM
Patrick Daly
Myeloma
|
December 7, 2023
Jens Hillengass, MD, PhD, covers updates from CARTITUDE that show cilta-cel is effective in early lines of therapy in MM.
View More
Analysis Finds Current Treatments Lacking for Multiple Myeloma with Extramedullary Disease
Patrick Daly
Myeloma
|
December 6, 2023
Researchers point to the poor outcomes observed with existing treatments. Here's what they found.
Read More
Open-Access Data Support the Use of Brexu-cel in MCL
Patrick Daly
Aggressive B-Cell Lymphoma
|
December 5, 2023
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.
Read More
Venetoclax Plus Azacitidine Achieves High Response Rates in Untreated High-Risk MDS
Patrick Daly
Myelodysplastic Syndromes
|
December 5, 2023
Venetoclax plus azacitidine was well tolerated and achieved favorable response rates in higher-risk myelodysplastic syndrome.
Read More
Navitoclax with Ruxolitinib Greatly Improves Spleen Response Versus Placebo in Myelofibrosis
Patrick Daly
Myelofibrosis
|
December 5, 2023
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
Read More
Momelotinib Provides Greater Transfusion Independence, Stability in MF
Patrick Daly
Myeloproliferative Neoplasms
|
December 6, 2023
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Read More
Older Patients with Acute Myeloid Leukemia Have Distinct Mutational Landscape
Patrick Daly
Acute Myeloid Leukemia
|
December 1, 2023
Researchers identified which co-occurring mutations had the strongest significance and what the high incidence could mean.
Read More
Cilta-cel Improved Outcomes in Pretreated Multiple Myeloma Compared with Standard Care
Patrick Daly
Myeloma
|
November 29, 2023
Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.
Read More
Carfilzomib Shows Benefits Over Bortezomib in Triplet Induction Therapy for Multiple Myeloma
Patrick Daly
Myeloma
|
November 29, 2023
Carfilzomib improved PFS versus bortezomib in induction therapy regimens with lenalidomide and dexamethasone in MM.
Read More
Study Suggests Lenalidomide-Associated ALL Is Frequent but Manageable
Patrick Daly
Myeloma
|
November 29, 2023
Lenalidomide-associated ALL was seen in patients with MM, but discontinuation alone led to regression of clonal populations.
Read More
Patients with CLL Lack Known Resistance Mechanisms After Disease Progression
Patrick Daly
Chronic Lymphocytic Leukemia
|
November 28, 2023
Patients with CLL who progressed after ibrutinib and venetoclax did not show mutations linked with treatment resistance.
Read More
First Data on Nemtabrutinib in Relapsed or Refractory Hematologic Malignancies
Patrick Daly
Chronic Lymphocytic Leukemia
|
November 28, 2023
Nemtabrutinib induced a response in 75% of patients with CLL, and investigators established a phase II dose of 65 mg daily.
Read More
High Response Rates with Time-Limited Triplet Combination in CLL
Patrick Daly
Chronic Lymphocytic Leukemia
|
November 28, 2023
A time-limited regimen including a PI3K inhibitor was safe and highly effective in patients with relapsed or refractory CLL.
Read More
MajesTEC-1 Data Support Teclistamab Efficacy with Less Frequent Dosing
Patrick Daly
Myeloma
|
November 28, 2023
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Read More
Promising Response Rates with Mosunetuzumab Plus Polatuzumab Vedotin in MCL
Patrick Daly
Mantle Cell Lymphoma
|
November 21, 2023
Mosunetuzumab plus polatuzumab vedotin achieved high CR rates in relapsed or refractory MCL with prior BTKi treatment.
Read More
Alternating Cytarabine in R-CHOP Induction Therapy Seems Marginal for Elderly Patients
Patrick Daly
Mantle Cell Lymphoma
|
November 21, 2023
Interspersing cytarabine in R-CHOP induction therapy did not yield significant improvements in elderly patients with MCL.
Read More
Outpatient MCL Treatment Regimen Induces Responses in Mutated MCL
Patrick Daly
Mantle Cell Lymphoma
|
November 21, 2023
BOVen induced high rates of response and MRD-negativity among patients with untreated MCL with TP53 mutations.
Read More
Pooled Analysis Shows Elranatamab ‘Effective’ in Relapsed, Refractory Myeloma
Patrick Daly
Myeloma
|
November 16, 2023
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Read More
Final Analysis of IFNα Versus Conventional Hydroxyurea in Myeloproliferative Neoplasms
Patrick Daly
Myelofibrosis
|
November 16, 2023
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
Read More
Load More